Antitumor Effect Of Interferon-belta CDNA Engineered Human Bone Marrow Mesenchymal Stem Cells To Prostate Cancer Cell Line PC-3

Objective: To investigate the effect of human interferon-beta gene cDNA engineered human bone marrow mesenchymal stem cells inhibit the growth of prostate cancer cell line PC-3 in vitro, and investigate a therapeutic strategy about the local production of biological agents in prostate cancer by gene-manipulated hMSCs.Methods: The pCDNA3.1-IFN-βvector containing huIFN-βgene was constructed and transfected into hMSCs by lipofectamine. Effects of IFN-?- hMSCs on survival of the human prostate cancer cell line PC-3 based on in vitro Transwell experiments. PC-3 cells were trypsinized and viable cells were counted respectively at 1, 3, and 5 days using a hemocytometer after trypan blue staining. The expression of IFN-? in the medium of hMSCs-IFN-? was detected by ELISA.Results: IFN-?-hMSCs resulted in a significant decrease in PC-3 cells survival as compared with control group [5 days after plating, the count of PC-3 cells which co-culture with IFN-?-hMSCs significantly decreased from 0.5×106 to (0.42±0.032)×106, and the number of PC-3 cells cultured alone or co-cultured with hMSCs, P-hMSCs, IFN-? increased in a different level]. Flow cytometry analysis showed that the IFN-?-hMSCs induced effectively the apoptosis of tumor cells (40.29%). Medium was collected and assayed using a quantitative ELISA assay for IFN-?,IFN-?-hMSCs produced 3～4×103 IU of IFN-? per 105 MSCs during the first 24 h after infection. However, there was no detectable content of IFN-? in control group. Conclusions: We conclude that hMSCs can integrate into prostate cancer microenviroment in vivo. The hMSCs can express IFN-? successfully after huIFN-? gene transfection and IFN-?-hMSCs cells inhibit the prostate cancer cells growth significantly as compared with control group in vitro, which may develop a new investigative strategy about gene therapy to prostate cancer.